Harrow, Inc. Estimated Litigation Liability
Harrow, Inc. (HROW) had Estimated Litigation Liability of $1.50 million as of 2021-11-08, per its 10-K filed 2023-03-23.
Discontinued › Balance Sheet › Liabilities
us-gaap:LitigationReserve · last filed 2023-03-23
- 2021-11-08: Estimated Litigation Liability $1.50M.
- 2021-09-30: Estimated Litigation Liability $1.50M.
| Period end | Estimated Litigation Liability |
|---|---|
| 2021-11-08 | $1.50M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.50M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |